Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Prothena Corporation plc - Ordinary Shares (NQ:PRTA)

9.340 -0.200 (-2.10%)
Streaming Delayed Price Updated: 12:30 PM EST, Dec 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Prothena Corporation plc - Ordinary Shares

< Previous 1 2 3 Next >
News headline image
Prothena Announces Board of Directors Update
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Reports Third Quarter 2025 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena to Report Third Quarter 2025 Financial Results on November 6
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Reports Second Quarter 2025 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena to Report Second Quarter 2025 Financial Results on August 4
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Announces Corporate Restructuring
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Reports First Quarter 2025 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena to Report First Quarter 2025 Financial Results on May 8
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Announces Board of Directors Update
From Prothena Corporation plc
Via Business Wire
News headline image
Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Reports Third Quarter 2024 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena to Report Third Quarter 2024 Financial Results on November 12
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Announces Leadership Team Updates
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena to Participate in Upcoming Healthcare Conferences
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Reports Second Quarter 2024 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena to Report Second Quarter 2024 Financial Results on August 8
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Reports First Quarter 2024 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena to Report First Quarter 2024 Financial Results on May 8
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
From Prothena Corporation plc
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.